Free Trial
NASDAQ:AFIB

Acutus Medical (AFIB) Stock Price, News & Analysis

Acutus Medical logo
$0.05 0.00 (-7.59%)
As of 02/21/2025 03:54 PM Eastern

About Acutus Medical Stock (NASDAQ:AFIB)

Key Stats

Today's Range
$0.05
$0.06
50-Day Range
$0.04
$0.07
52-Week Range
$0.03
$0.27
Volume
48,095 shs
Average Volume
48,442 shs
Market Capitalization
$1.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

Receive AFIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acutus Medical and its competitors with MarketBeat's FREE daily newsletter.

AFIB Stock News Headlines

Acutus Medical Announces Operational Downsizing
Acutus Medical Reports Q3 2024 Financial Results
Shocking Elon Move: Bigger than DOGE?
After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recent DOGE moves… What Elon Musk is about to do next could not only shock the world… But also put an extra $30,000 a year in your pocket.
See More Headlines

AFIB Stock Analysis - Frequently Asked Questions

Acutus Medical's stock was trading at $0.0550 at the start of the year. Since then, AFIB shares have decreased by 2.5% and is now trading at $0.0536.
View the best growth stocks for 2025 here
.

Acutus Medical, Inc. (NASDAQ:AFIB) posted its quarterly earnings data on Thursday, November, 11th. The company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.02. The company earned $4.60 million during the quarter, compared to analyst estimates of $6.02 million. Acutus Medical had a negative net margin of 272.74% and a negative trailing twelve-month return on equity of 311.64%.

Acutus Medical subsidiaries include these companies: Acutus Medical N.V..

Acutus Medical (AFIB) raised $126 million in an initial public offering (IPO) on Thursday, August 6th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, BofA Securities and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Shares of AFIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Acutus Medical investors own include Enterprise Products Partners (EPD), NVIDIA (NVDA), Arista Networks (ANET), Meta Platforms (META), Nextera Energy Partners (NEP), PayPal (PYPL) and Rio Tinto Group (RIO).

Company Calendar

Last Earnings
11/11/2021
Today
2/22/2025
Next Earnings (Estimated)
3/31/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AFIB
Employees
340
Year Founded
2011

Profitability

Net Income
$-81,660,000.00
Net Margins
-272.74%
Pretax Margin
-30.32%

Debt

Sales & Book Value

Annual Sales
$7.16 million
Book Value
($0.03) per share

Miscellaneous

Free Float
28,228,000
Market Cap
$1.60 million
Optionable
Optionable
Beta
-0.18

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AFIB) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners